122 related articles for article (PubMed ID: 20543544)
21. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy.
Weisser M; Schleuning M; Haferlach C; Schwerdtfeger R; Kolb HJ
Leuk Lymphoma; 2007 Feb; 48(2):295-301. PubMed ID: 17325889
[TBL] [Abstract][Full Text] [Related]
23. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
Rytting ME; Wierda WG
Leuk Lymphoma; 2004 Aug; 45(8):1623-6. PubMed ID: 15370215
[TBL] [Abstract][Full Text] [Related]
24. Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging.
Kreuzer KA; Klühs C; Baskaynak G; Movassaghi K; Dörken B; le Coutre P
Br J Haematol; 2004 Jan; 124(2):195-9. PubMed ID: 14687030
[TBL] [Abstract][Full Text] [Related]
25. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.
Giona F; Putti MC; Micalizzi C; Menna G; Moleti ML; Santoro N; Iaria G; Ladogana S; Burnelli R; Consarino C; Varotto S; Tucci F; Messina C; Nanni M; Diverio D; Biondi A; Pession A; Locatelli F; Piciocchi A; Gottardi E; Saglio G; Foà R
Br J Haematol; 2015 Aug; 170(3):398-407. PubMed ID: 25891192
[TBL] [Abstract][Full Text] [Related]
26. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
[TBL] [Abstract][Full Text] [Related]
27. Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy.
Takahashi N; Miura I; Kobayashi Y; Kume M; Yoshioka T; Otane W; Ohtsubo K; Takahashi K; Kitabayashi A; Kawabata Y; Hirokawa M; Nishijima H; Ichinohasama R; Decoteau J; Miura AB; Sawada K
Int J Hematol; 2005 Apr; 81(3):235-41. PubMed ID: 15814334
[TBL] [Abstract][Full Text] [Related]
28. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.
Carpenter PA; Snyder DS; Flowers ME; Sanders JE; Gooley TA; Martin PJ; Appelbaum FR; Radich JP
Blood; 2007 Apr; 109(7):2791-3. PubMed ID: 17119111
[TBL] [Abstract][Full Text] [Related]
29. Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation.
Koc Y; Miller KB; Schenkein DP; Daoust P; Sprague K; Berkman E
Cancer; 1999 Feb; 85(3):608-15. PubMed ID: 10091734
[TBL] [Abstract][Full Text] [Related]
30. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.
Zonder JA; Pemberton P; Brandt H; Mohamed AN; Schiffer CA
Clin Cancer Res; 2003 Jun; 9(6):2092-7. PubMed ID: 12796373
[TBL] [Abstract][Full Text] [Related]
31. Relapse and cytogenetic evolution in myeloid neoplasms.
Ertz-Archambault N; Kelemen K
Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
[TBL] [Abstract][Full Text] [Related]
32. Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate.
Brazzelli V; Muzio F; Manna G; Moggio E; Vassallo C; Orlandi E; Fiandrino G; Lucioni M; Borroni G
Photodermatol Photoimmunol Photomed; 2012 Feb; 28(1):2-5. PubMed ID: 22211996
[TBL] [Abstract][Full Text] [Related]
33. Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.
Faber E; Nausová J; Jarosová M; Egorin MJ; Holzerová M; Rozmanová S; Maresová I; Divoký V; Indrák K
Leuk Lymphoma; 2006 Jun; 47(6):1082-90. PubMed ID: 16840200
[TBL] [Abstract][Full Text] [Related]
34. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
35. Localized lymphoid relapse in the pancreas following allogeneic hematopoietic stem cell transplant for chronic myelogenous leukemia.
Rossetti JM; Lister J; Shadduck RK; Bloom E; Geyer SJ; Caushaj PF; Homann J; Papasavas P; Cedar M
Leuk Lymphoma; 2003 Jun; 44(6):1071-4. PubMed ID: 12854913
[TBL] [Abstract][Full Text] [Related]
36. Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation.
Medeiros BC; Chun K; Kamel-Reid S; Lipton J
Am J Hematol; 2007 Aug; 82(8):758-60. PubMed ID: 17301975
[TBL] [Abstract][Full Text] [Related]
37. Targeted therapies: Imatinib prior to allogeneic HSCT therapy improves both relapse and nonrelapse survival in patients with Ph+ ALL.
Killock D
Nat Rev Clin Oncol; 2014 May; 11(5):241. PubMed ID: 24642681
[No Abstract] [Full Text] [Related]
38. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
Savani BN; Montero A; Kurlander R; Childs R; Hensel N; Barrett AJ
Bone Marrow Transplant; 2005 Dec; 36(11):1009-15. PubMed ID: 16205732
[TBL] [Abstract][Full Text] [Related]
39. Granulocytic sarcoma in a patient with chronic myeloid leukaemia in complete haematological, cytogenetic and molecular remission.
Kittai A; Yu EM; Tabbara I
BMJ Case Rep; 2014 Dec; 2014():. PubMed ID: 25538217
[TBL] [Abstract][Full Text] [Related]
40. Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.
Ramanarayanan J; Dunford LM; Baer MR; Sait SN; Lawrence W; McCarthy PL
Leuk Res; 2006 Jun; 30(6):701-5. PubMed ID: 16330096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
